Rod J Azadan1, Nadia H Agha2, Hawley E Kunz3, Forrest L Baker1,4,5,6, Preteesh L Mylabathula1,4, Tracy A Ledoux1, Daniel P O'Connor1, Charles R Pedlar7,8, Richard J Simpson9,10,11,12. 1. Laboratory of Integrated Physiology, Department of Health and Human Performance, University of Houston, 3875 Holman Street, Houston, TX, 77204, USA. 2. Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX, USA. 3. Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA. 4. Department of Nutritional Sciences, University of Arizona, Tucson, AZ, USA. 5. Department of Pediatrics, University of Arizona, Tucson, AZ, USA. 6. Department of Immunobiology, University of Arizona, Tucson, AZ, USA. 7. Faculty of Sport, Health and Applied Science, St Mary's University, Twickenham, England, UK. 8. Institute of Sport, Exercise and Health, University College London (UCL), London, England, UK. 9. Laboratory of Integrated Physiology, Department of Health and Human Performance, University of Houston, 3875 Holman Street, Houston, TX, 77204, USA. rjsimpson@arizona.edu. 10. Department of Nutritional Sciences, University of Arizona, Tucson, AZ, USA. rjsimpson@arizona.edu. 11. Department of Pediatrics, University of Arizona, Tucson, AZ, USA. rjsimpson@arizona.edu. 12. Department of Immunobiology, University of Arizona, Tucson, AZ, USA. rjsimpson@arizona.edu.
Abstract
PURPOSE:Habitual endurance exercise results in increased erythropoiesis, which is primarily controlled by erythropoietin (EPO), yet studies demonstrating upregulation of EPO via a single bout of endurance exercise have been equivocal. This study compares the acute EPO response to 30 min of high versus 90 min of moderate-intensity endurance exercise and whether that response can be upregulated via selective adrenergic receptor blockade. METHODS: Using a counterbalanced, cross-over design, fifteen participants (age 28 ± 8) completed twobouts of running (30-min, high intensity vs 90-min, moderate intensity) matched for overall training stress. A separate cohort of fourteen participants (age 31 ± 6) completed threebouts of 30-min high-intensity cycling after ingesting the preferential β1-adrenergic receptor (AR) antagonist bisoprolol, the non-preferential β1 +β2 antagonist nadolol or placebo. Venous blood was collected before, during, and after exercise, and serum EPO levels were determined by ELISA. RESULTS: No detectable EPO response was observed during or after high intensity running, however, in the moderate-intensity trial EPO was significantly elevated at both during-exercise timepoints (+ 6.8%± 2.3% at 15 min and + 8.7%± 2.2% at 60 min). No significant change in EPO was observed post-cycling or between the trials involving βAR blockade. CONCLUSION: Neither training mode (running or cycling), nor beta-blockade significantly influenced the EPO response to 30 min of high-intensity exercise, however, 90 min of moderate-intensity running elevated EPO during exercise, returning to baseline immediately post-exercise. Identifying the optimal mode, duration and intensity required to evoke an EPO response to exercise may help tailor exercise prescriptions designed to maximize EPO response for both performance and clinical applications.
RCT Entities:
PURPOSE: Habitual endurance exercise results in increased erythropoiesis, which is primarily controlled by erythropoietin (EPO), yet studies demonstrating upregulation of EPO via a single bout of endurance exercise have been equivocal. This study compares the acute EPO response to 30 min of high versus 90 min of moderate-intensity endurance exercise and whether that response can be upregulated via selective adrenergic receptor blockade. METHODS: Using a counterbalanced, cross-over design, fifteen participants (age 28 ± 8) completed two bouts of running (30-min, high intensity vs 90-min, moderate intensity) matched for overall training stress. A separate cohort of fourteen participants (age 31 ± 6) completed three bouts of 30-min high-intensity cycling after ingesting the preferential β1-adrenergic receptor (AR) antagonist bisoprolol, the non-preferential β1 + β2 antagonist nadolol or placebo. Venous blood was collected before, during, and after exercise, and serum EPO levels were determined by ELISA. RESULTS: No detectable EPO response was observed during or after high intensity running, however, in the moderate-intensity trial EPO was significantly elevated at both during-exercise timepoints (+ 6.8% ± 2.3% at 15 min and + 8.7% ± 2.2% at 60 min). No significant change in EPO was observed post-cycling or between the trials involving βAR blockade. CONCLUSION: Neither training mode (running or cycling), nor beta-blockade significantly influenced the EPO response to 30 min of high-intensity exercise, however, 90 min of moderate-intensity running elevated EPO during exercise, returning to baseline immediately post-exercise. Identifying the optimal mode, duration and intensity required to evoke an EPO response to exercise may help tailor exercise prescriptions designed to maximize EPO response for both performance and clinical applications.
Authors: Keren Constantini; David A Tanner; Timothy P Gavin; Craig A Harms; Joel M Stager; Robert F Chapman Journal: Med Sci Sports Exerc Date: 2017-05 Impact factor: 5.411
Authors: Monika Ciekot-Sołtysiak; Krzysztof Kusy; Tomasz Podgórski; Jacek Zieliński Journal: J Sports Med Phys Fitness Date: 2017-10-24 Impact factor: 1.637
Authors: Hoi I Cheong; Kewal Asosingh; Olivia R Stephens; Kimberly A Queisser; Weiling Xu; Belinda Willard; Bo Hu; Josephine Kam Tai Dermawan; George R Stark; Sathyamangla V Naga Prasad; Serpil C Erzurum Journal: JCI Insight Date: 2016-12-22
Authors: Nadia H Agha; Forrest L Baker; Hawley E Kunz; Rachel Graff; Rod Azadan; Chad Dolan; Mitzi S Laughlin; Chitra Hosing; Melissa M Markofski; Richard A Bond; Catherine M Bollard; Richard J Simpson Journal: Brain Behav Immun Date: 2017-10-07 Impact factor: 7.217